Inclusion Criteria:  Written informed consent signed prior to the performance of any study procedures Male or female volunteers, age 18 to 65 years, inclusive Overweight to obese (BMI 28.0 - 40.0 kg/m2) Type 2 diabetes mellitus (T2DM), on stable regimen, for at least 3 months prior to screening, of any combination of (1) diet and exercise, (2) metformin with absent or mild gastrointestinal symptoms (nausea, vomiting or diarrhea), and/or (3) sodium glucose cotransporter-2 (SGLT-2) therapy Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control  Exclusion Criteria:  Type 1 diabetes mellitus (DM) and/or insulin-dependent T2DM, or uncontrolled T2DM defined as hemoglobin A1c (HbA1c) ≥ 9.5% or C-peptide ≤ 8 ng/mL History of acute or chronic pancreatitis or hypersensitivity reaction to GLP-1 analogues